DOME: Recommendations for supervised machine learning validation in
  biology by Walsh, Ian et al.
Recommendations for machine learning validation in 
biology 
Ian Walsh​1,*​, Dmytro Fishman​2,*​, Dario Garcia-Gasulla​3​, Tiina Titma​4​, The ELIXIR Machine Learning 
focus group​#​, Jen Harrow​5,+​, Fotis E. Psomopoulos​6,+​ & Silvio C.E. Tosatto​7,+ 
 
1​ Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, ​2​ Institute of 
Computer Science, University of Tartu, Estonia,  ​3​ Barcelona Supercomputing Center (BSC), Barcelona, Spain,  ​4 
School of Information Technologies, Tallinn University of Technology, Estonia, ​5​ ELIXIR HUB, South building, 
Wellcome Genome Campus, Hinxton, Cambridge, UK, ​6​ Institute of Applied Biosciences, ​6​ Centre for Research 
and Technology Hellas, Thessaloniki, Greece, ​7​ Dept. of Biomedical Sciences, University of Padua, Padua, Italy. 
*​contributed equally 
#​see list of co-authors at the end of the manuscript 
+ ​corresponding authors 
 
Abstract 
Modern biology frequently relies on machine learning to provide predictions and improve decision             
processes. There have been recent calls for more scrutiny on machine learning performance and possible               
limitations. Here we present a set of community-wide recommendations aiming to help establish             
standards of machine learning validation in biology. Adopting a structured methods description for             
machine learning based on DOME (data, optimization, model, evaluation) will allow both reviewers and              
readers to better understand and assess the performance and limitations of a method or outcome. The                
recommendations are complemented by a machine learning summary table which can be easily included              
in the supplementary material of published papers.  
 
Introduction  
With the steep decline in the cost of high-throughput technologies, large amounts of biological data are                
being generated and made accessible to researchers. Analyzing this highly complex and voluminous data              
is not trivial, while the use of classical statistics is not enough to explore their full potential. Machine                  
learning (ML) has thus been brought into the spotlight as a very useful approach to understand cellular​1​,                 
genomic​2​, proteomic ​3​, post-translational​4​, metabolic​5 and drug discovery data​6 with the potential to result             
in ground-breaking medical applications​7,8 (Supp. Figure 1). This is clearly reflected in the corresponding              
growth of ML publications (Figure 1), reporting a wide range of modelling techniques in biology.               
However, this sharp increase in publications inherently requires a corresponding increase in the number              
and depth of experts’ reviews that can offer critical assessment​9 and improve reproducibility​10​.             
Consequently, there are ML applications published and used today that contain substantial flaws often              
producing true prediction performances worse than claimed or even worse than random estimates​11,12​.  
A complete set of standard guidelines and best practices is still a matter of debate. However, some                 
concerns that arise in ML are universally agreed. For example, in a sample of over 400 papers submitted                  
at major AI conferences only 6% shared their code, one third shared their data, and around half shared                  
pseudocode​13​. This lack of availability is resulting in a reproducibility crisis as critical components of ML                
models are not shared with the community​13–15​. Perhaps, the biggest reason for the lack of sharing is the                  
vast commercial value of useful ML models​16 and their potential impact. Data characteristics such as               
train/test set independence, size, distribution and quality are often under-reported​17​. Recent deep learning             
ML approaches are suited to extract knowledge from large volumes of data but depend on underlying                
data quality​18​. Conversely, being able to generalise from small training sets is also receiving interest               
recently​19​. Data quality may be affected by unbalance in terms of classes, poor quality or noisy                
observations, or may not be released to the public. Furthermore, biological data often offers only a partial                 
view of the problem at hand, which can easily introduce unrecognized biases on. It is therefore necessary                 
to perform rigorous quality checks before using ML. The interpretability of predictions also depends on               
the ML models being used, with a prevalence of back box results ​20​. Equally important is a reliable                 
evaluation of the model on data which is completely unrelated to the data used in training in order to                   
assess the final performance. Without a correct benchmark, ML models simply cannot be used for               
biological inference with guarantees. In practice, implementing ML models that can generalize well on              
unseen biological data is a challenging task that requires both significant proficiency in ML and               
biology​17​. 
A recent high-profile citation abuse case involving a scientist publishing ML methods has highlighted              
how the review process can be easily distorted at the moment for personal benefit​21​. Additionally, just last                 
year another article in Nature Reviews Molecular Cell Biology highlighted the need for stricter standards               
in ML​22​, arguing for the adoption of on-submission checklists​9 as a first step towards improving               
publication standards. In this direction, a universal checklist for ML on biological data is presented in                
Table 1 outlining four broad topics with recommended actions. We have focused on Data, Optimization,               
Model and Evaluation (DOME) as we found most errors in ML protocols occur in these. To remedy this                  
situation through a community-driven consensus, we propose a set of minimum information insights to              
be provided for ML papers, allowing reviewers and readers to assess the quality and reliability of the                 
proposed methods more faithfully. Our recommendations are made primarily for the case of supervised              
learning, as this is the most common type of ML approach used, but these can be easily extended to other                    
fields of ML, like unsupervised , semi-supervised learning, transfer learning and reinforcement learning.  
 
 
 
Figure 1. ​Exponential increase of ML publications in biology. The number of ML publications per year is based                  
on Web of Science from 1996 onwards using the “topic” category for “machine learning” in combination with each                  
of the following terms: “biolog*”, “medicine”, “genom*”, “prote*”, “cell*”, “post translational”, “metabolic” and             
“clinical”. 
 
 Broad topic Major 
concerns 
Consequences Recommendation(s)/requirement(s) 
Data  
- Appropriate 
partitioning​, 
dependence 
between train 
and test data, 
sufficient data 
size & quality 
 
- Class imbalance 
 
- No access to 
data 
● Unreliable or 
biased 
performance 
evaluation.​ ​Data 
not representative 
of domain 
application. 
 
● Cannot check 
data credibility. 
Independence of optimization (training) and evaluation (testing) 
sets. (​requirement) 
 
Especially important for meta algorithms, where independence 
of multiple training sets must be shown to be independent from 
the evaluation (testing) sets. Data size & distribution is 
representative of the domain​. (​requirement​) 
Release data preferably using appropriate long-term repositories, 
including exact splits (​requirement​) 
For data produced by different experimental runs the batch 
effect must be tested, by treating each set of experiments as not 
independent data  (​recommendation​) 
Optimization - Overfitting​, 
underfitting​ & 
Illegal 
parameter 
tuning 
 
- Imprecise 
parameters and 
protocols given. 
● Over/under 
optimistic 
performance 
reported. Model 
noise & miss 
relevant 
relationships. 
Evaluation datasets should not be used for either feature 
selection or parameter tuning. (​requirement​) 
Appropriate metrics to prove no over/under fitting, i.e. 
comparison of training and testing error. (​requirement) 
 Release definitions of all algorithmic hyper-parameters, 
parameters and optimization protocol (​requirement​) 
Include explicit model validation techniques, such as N-fold 
Cross validation (​recommendation​).  
Model - Models are 
blackboxs​ but 
transparency​ ​is 
required for 
certain problem 
 
- No access to: 
resulting ​source 
code​, trained 
models​ & ​data 
 
- Execution time 
is impractical 
● Models output 
some score which 
cannot be traced 
back to data. 
Perhaps, a 
transparent​ model 
is a better 
solution 
 
● Cannot: cross 
compare methods, 
reproducibility, 
& check data 
credibility.  
 
● Model takes too 
much time to 
produce results 
Blackbox models are interesting but certain problems need 
interpretable solutions (e.g. diagnostics). Blackbox vs. 
transparent should be decided before optimization. 
(​recommendation​).  
Hybrid blackbox and transparent models might be a balance. 
(​recommendation​). 
Release of: documented source code + models + executable + 
UI/webserver + software containers. (​recommendation​) 
Report execution time averaged across many repeats. If 
computationally tough compare to similar methods 
(​recommendation​) 
Evaluation - Performance 
measures​ not 
adequate 
 
- No comparisons 
to ​baselines​ or 
other methods 
 
● Biased 
performance 
measures 
reported.  
 
● The method is 
falsely claimed as 
Compare with public methods & simple models (baselines). 
(​requirement​)  
Adoption of ​community validated ​measures for evaluation. 
(​requirement​) 
- Highly ​variable 
performance​.  
state-of-the-art.  
 
● Then, 
unpredictable 
performance in 
production. 
Comparison of related methods and alternatives on the same 
dataset, ablation study for measuring the impact of components​. 
(​recommendation​) 
Data distribution checked for good domain representativeness. 
Confidence intervals/error intervals to gauge prediction 
robustness. (​recommendation​) 
  
Table 1. ML in the Biology: concerns, the consequences they impart and recommendations/requirements             
(recommendations in ​italics​ and requirements in ​bold​). Key terms ​underlined​.  
 
Development of the recommendations  
The recommendations outlined below were initially formulated through the ELIXIR ML focus group             
after the publication of a comment calling for the establishment of standards for ML in biology​22​.                
ELIXIR, initially established in 2014, is now a mature intergovernmental European infrastructure for             
biological data and represents over 220 research organizations in 22 countries across many aspects of               
bioinformatics​23​. Over 700 national experts participate in the development and operation of national             
services that contribute to data access, integration, training and analysis for the research community. Over               
50 of these experts involved in the field of ML have established an ELIXIR ML focus group                 
(​https://elixir-europe.org/focus-groups/machine-learning​) which held a number of meetings to develop         
and refine the recommendations based on a broad consensus among them.  
 
Scope of the recommendations  
The recommendations cover four separate aspects covering the major areas of ML according to the               
“DOME” acronym: data, optimization, model and evaluation. In the following, we will address each of               
these aspects separately. 
 
1. Data 
Machine learning models analyse experimental biological data by extracting patterns. The extracted            
patterns can then be used to give biological insights on similar data that were not previously seen by the                   
model. The degree to which a model retains its performance on new data is called ​generalization power.                 
Building ML models that generalize well is the main challenge of these methodologies, otherwise the               
trained models cannot be reused. Preprocessing data properly, and using it in a knowledgeable manner is                
the only way to obtain good generalization. Some basic concerns to consider are: 
 
● training, test and validation datasets are partially or completely overlapping. This includes both             
sequence/structure similarities and a set of experiments obtained in different conditions or batches             
(e.g. for next-generation sequencing data). 
● training dataset is too small to capture the full complexity of the underlying distribution. 
● validation and test datasets are too small to provide a stable estimate of the model’s generalization                
power. 
● training, validation and test sets are not representative of the problem domain due to e.g. presence                
of high noise levels, imbalanced classes, large chunks of similar (redundant) data points 
● data is not released to the public 
 
State-of-the-art ML models are often capable of memorizing all the variation in the given data. Such                
models when evaluated on data that they were exposed to during training would create an illusion of                 
mastering the task at hand. However, when tested on an independent set of data, the performance would                 
seem less impressive, suggesting low generalization power of the model. In order to tackle this problem,                
initial data is divided randomly into non-overlapping unequal parts. The larger set (usually about              
70-80%) is called training data and is used to shape the model, helping it achieve the highest possible                  
performance in the given task via optimization (see the next section). The data split, termed the test set, is                   
invariably smaller and it is left out from training. It is used only when it is time to estimate the true                     
generalization power of the final model. The resulting generalization score is considered realistic only if               
the test set was used once. Overlapping of train/test data splits is particularly troublesome in the case of                  
protein and DNA sequences that make up a large fraction of biological data and can be similar by                  
evolutionary homology. Thus, special methods such as redundancy reduction techniques can be used to              
mitigate this problem for sequences​9,16​. Furthermore, to ensure unbiased evaluation, when researchers            
want to train multiple models or select the best hyper-parameters, the training data is divided further to                 
form a validation set. Different models and hyper-parameters are then trained on the remaining part of the                 
training data, and evaluated on the validation set. Next, the best model is selected and evaluated on the                  
test data, producing the final performance result. Despite seeming bias-proof this scenario still leaves              
room for unwanted unfairness. Randomly choosing a single validation set may favour some models,              
while opposing others. The cross-validation or bootstrapping techniques which choose a new validation             
set multiple times from the available training data, is thus considered a preferred solution ​24​.  
The size ​of all three subsets of data, namely training, validation and test sets is of great importance​. A too                    
small training set may prevent the model from reaching its full potential. While having too small test and                  
validation sets, may result in unstable performance estimates. When data is limited (which often can be                
the case in biology and medicine), a fine balance between the size of train and validation/test splits is                  
required. Having said this, the problem of training ML models that can generalize well in so called small                  
training data, usually requires special models and algorithms​19,25​.  
Another important indicator to keep in mind when preparing data for the ML model is the degree to                  
which training data truly represents the domain of the problem, related to a ​representative ​sample of a                 
population in statistics​26​. Namely, if training data is significantly different from the data that the model                
will encounter in the future, for example, due to the presence of excessive amounts of noise or skewed                  
distributions of input and output, the model’s generalization power will be limited. In the case where                
input features and output class distributions significantly differ from what is found in the literature (or                
more importantly in nature), it is often necessary to make sure that training, validation and test sets are                  
pre-processed/sampled to be representative. This can be again achieved by adding or removing data              
points that create the skew. To this end, thorough exploration analysis as well as quality control need to                  
be performed to make sure that data is trustworthy.  
Lastly, it is important to make as much data available for the public as possible. Having open access to                   
the data used for experiments including precise data splits would ensure better reproducibility of              
published research and as a result will improve the overall quality of published ML papers. If datasets are                  
not already available at any public repository, authors should be encouraged to find the most appropriate                
one, e.g. ELIXIR Deposition databases or Zenodo, to guarantee the long-term availability of such data. 
  
There are several strategies that can be employed to mitigate the issues described above in order to ensure                  
correct data organization: 
1. Create two distinct sets of data: training and test sets (requirement). If the training process               
implicitly requires a validation set (e.g. multiple models are optimized; hyper-parameters are            
optimized), an additional validation set is needed. Alternatively, consider applying a           
cross-validation algorithm.  
2. Report size of the data as well as the size of resulting training and test (and if applicable                  
validation) sets. Search in the literature and report data sizes used to train similar ML methods.  
3. Plot the distributions of the data points (e.g. number of patients vs number of controls, age of                 
patients, protein structure types) in the train and test sets to indicate the type of data the model can                   
handle. Make sure, given the problem domain, there is good representation in both sets. This is a                 
highly recommended strategy, as it can clearly show whether the data size and distribution is               
representative of the respective problem domain, e.g., methods exist that address imbalanced            
classes​27,28​. 
4. Perform quality control and report indicators that can help to assess the quality of the dataset (e.g.                 
resolution of images or sequence annotation source etc.). 
5. It is a requirement to release the train/test/validation splits exactly as described. If cross-validation              
is performed the exact folds should be released as described.  
 
 
2. Optimization 
Optimization, also known as model training, refers to the process of changing values that constitute the                
model (parameters and hyper-parameters of the model) in a way that maximizes the model’s ability to                
solve a given problem. In this section, we will focus on problems associated with a poor choice of                  
optimization strategy. Such problems may include: 
● selecting a too powerful model, that may over-fit (known as high-variance​29​)  
● selecting a too simple model, that may under-fit (known as high-bias​29​) 
● parameters are optimized and/or features are selected on hold-out data used to evaluate             
performance only. This may be particularly hard to spot for meta-predictors.  
● parameters, hyper-parameters and optimization protocol are not specified and/or files supporting           
their specification are not open-access or follow a standard widely adopted by the community (if               
any). 
 
Since model parameters are openly optimized to achieve the best possible performance on the training               
data, it is common for models to perform better on training sets than on validation or test sets. With more                    
complex and hence powerful algorithms the gap between performance on training and on hold out data                
grows. In ML, this gap is indicative of over-fitting. This is particularly difficult to spot in                
meta-algorithms, such as boosting or majority voting for an ensemble of classifiers, where it is not                
immediately clear if the hold-out set is independent of multiple training sets. Over-fitting usually happens               
due to the capacity of more complex models to learn ​arbitrary patterns in the training data, including                    
random noise, sampling artifacts or distributions of small data not representative of the underlying              
domain. A model that has suffered severe over-fitting will show an extraordinary performance on training               
data, while performing poorly on unseen data, rendering it useless for real-life applications. On the other                
side of the spectrum is a problem of under-fitting. Under-fitting occurs when very simple models capable                
of capturing only straightforward dependencies between features are applied to data of a more complex               
nature (e.g logistic regression or linear classifiers are considered simple models). The number of input               
features (​f​) and feature encoding schemes are also a factor for optimization since (1) good feature                
representations make for good optimization and (2) because large ​f often implies a large number of                
parameters and in turn algorithm complexity. Thus, algorithms for feature selection​30 can be employed to               
reduce the chances of over-fitting. However, feature selection comes with its own concerns, the main one                
being illegal selection on non-training data which may lead to an overestimation of performance. Finally,               
the release of files showing the exact specification of the optimization protocol and the type of                
parameters/hyper-parameters are a vital characteristic of the final algorithm. ​For instance, ​neural            
networks can have a differing number of neurons with different activation functions and weight updating               
settings; support vector machines can have varying margin hyperplane sizes, input kernels and margin              
computations; and random forests can have a variable number of trees of varied depth.  
 
Some key recommendations that may help to detect and mitigate problems with optimization: 
● When building models, estimate and compare performances on both training and validation sets             
(large difference usually suggests over-fitting, while low overall performance on both points            
towards under-fitting). 
● If your model suffers from under-fitting, choose a more complex ML algorithm (e.g. with more               
parameters). If you diagnosed over-fitting, either select a simpler algorithm, use more data or data               
augmentation or reduce your model’s complexity (e.g. in neural networks move from deep to              
shallow neural networks or apply regularization). Note that choosing between different algorithms            
must be done on training or validation data in order to not introduce bias. 
● If over-fitting persists, attempt to increase the size or quality, reduce the number of input features                
of the training data and re-train. 
● It is a requirement that exact details of optimized parameters/hyper-parameters and optimization            
protocols are described.  
● It is a requirement that the protocol to reduce input features to the ‘best’ ones and parameter                 
tuning is done on training data only. For meta-algorithms, this must be performed clearly if all                
train sets are available.  
● It is good practice to release models (i.e. saved model files) at the initial and final training point.                  
These files can include regular parameters and hyper-parameter configurations, optimization          
protocols and selected features.  
 
3. Model 
Good overall performance of the trained model and its ability to generalize well to unseen data are                 
important factors that undoubtedly affect the applicability of any proposed ML research. However, a few               
other important aspects related to ML models must be kept in mind. These include the following                
fallacies: 
  
● Employing unexplainable models (blackbox) for areas where interpretability is required. 
● The various components of a model (source code, model files, parameter configurations,            
executables) are not made available to the public.  
● Computational requirements to execute the trained models (generate prediction based on new            
data) are impractical. 
 
ML models differ significantly in their ability to explain learned patterns back to humans. Hence, two                
main classes of ML models are recognized: transparent and blackbox​31​. For example, one may easily               
interpret a prediction made by linear regression or a decision tree; however, a model based on neural                 
networks or support vector machines can be effectively considered a blackbox. This by itself is not an                 
issue - a blackbox model can be very effective in a particular context (e.g. image recognition). On the                  
other hand certain problems and particular studies require model transparency in order to claim              
knowledge breakthrough. Interpretability is particularly relevant in areas of discovery such as drug             
design ​6,32 and diagnostics​33 where inferring causal relationships from observational data is of utmost             
importance. Many approaches were proposed that aim at opening the blackboxes​34,35​. However, despite             
growing interest in explaining blackbox models, a recent perspective has proposed to enable transparency              
by employing interpretable models in the first place​20​. Conversely, opinions on the adoption of blackbox               
models under specific circumstances have been voiced​36​. Depending on the value of the outcome,              
blackbox models may help to remove subjective factors from controversial decision-making, and offer             
the potential to inspire  and  guide  human  inquiry.  
For a newly reported, state-of-the-art performing model, restricting open-access of its underlying            
components such as source code, trained model files that include hyper-parameter configurations, and a              
means to run the algorithm is a major obstacle for furthering scientific goals in ML. The consequences                 
that arise here are the inability to reproduce the method, build improved versions, benchmark its               
performances or even use it for biological insight. Finally, the model's speed of execution is also another                 
factor especially in biologically domains that require large-scale predictions to make hypotheses.  
 
Some key recommendations towards addressing these issues are the following: 
1. There should always be a clear selection process between the choice of blackbox vs transparent               
models. Blackbox models are interesting but certain challenges and approaches require           
interpretable solutions (such as within a diagnostic context). 
2. It is highly recommended to give special attention to models that offer mechanistic insights on the                
internal data, over blackbox models. This consequently implies that thinking of ways to interpret              
predictions needs to be planned ahead. 
3. It is highly recommended to include a performance comparison between blackbox and transparent             
models, in order to gauge the tradeoff (e.g. between the choice of neural networks vs decision                
trees). 
4. It is recommended that documented source code should be released unless it is undergoing              
commercialization in which case statements in ‘conflict of interest’ sections of articles should be              
made.  
5. It is recommended that executables, web-servers, virtual machines and software container           
instances that can run the ML algorithm are released so that they can be used for cross comparison                  
of methods. The algorithms run time on standard PC CPUs should also be reported for a typical                 
set of data points.  
 
 
 
 
  
 
Figure 2. (Top) Classification metrics. ​For binary classification, true positives (tp), false positives (fp), false               
negatives (fn) and true negatives (tn) together form the confusion matrix. As all classification measures can be                 
calculated from combinations of these four basic values, the confusion matrix should be provided as a core metric.                  
Several measures (shown as equations) and plots should be used to evaluate the ML methods. If the article                  
becomes too cluttered, many of the metrics can be moved to supplementary material. For descriptions on how to                  
attempt these metrics to multi-class problems see ​37​. ​(Bottom) Regression metrics. ​ML regression attempts to               
produce predicted values (pv) matching experimental values (ev). Metrics (shown as equations) attempt to capture               
the difference in various ways. Alternatively, a plot can provide a visual way to represent the differences. It is                   
advisable to report all in any ML work.  
 
 
4. Evaluation 
In the implementation of a robust and trustworthy ML method, a comprehensive data description, a               
correct optimization protocol, and a clearly defined (and open-access) model are critical first steps;              
however, equally important is a valid assessment methodology for any final model. Here are a few                
possible risks related to model assessment and evaluation:  
● the selected performance measures are not adequate or comprehensive for the problem at hand 
● reported performances are highly unstable.  
● obtained performances are not compared to similar studies, methods and community-agreed           
datasets; obtained performances are not compared to simpler baseline methods. 
 
Performance metrics are quantifiable indicators of a model's ability to solve the given task. For assessing                
different ML problems (e.g. classification or regression) dozens of metrics are available​37​. Sometimes it is               
challenging to select the right measure from the exhaustive list, while on other occasions researchers may                
be tempted to use specific metrics which may provide a more favourable account of their model                
performance (i.e. cherry-picking). In either way, the resulting estimate may be neither valid nor useful.               
Currently, it is up to the peer-reviewer to check if reasonable metrics were employed. But as the choice of                   
metric tends to be domain-specific, reviewers should not be expected to always know the most suitable                
ones. In this work, we propose a consensus-based list of metrics that should be applied for classification                 
and regression types of ML, Figure 2. Simultaneously, confidence intervals or variance/standard            
deviations should be associated with each metric to show prediction stability. 
Once performance metrics are decided, methods published in the same biological domain must be              
cross-compared using appropriate statistical tests (e.g. Student's t-test). Additionally, to prevent the            
release of ML methods that appear sophisticated but perform no better than simpler algorithms, baselines               
should be compared to the ‘sophisticated’ method and proven to be statistically inferior (e.g. logistic               
regression vs. small NN vs. deep NN).  
 
Some key recommendations towards this direction are: 
● Performance metrics, selected for assessing model performance should be clearly reported and the             
choice should be justified. Figure 2 shows a list of reasonable performance measures for              
classification and regression tasks. 
● A case when the training data is imbalanced (i.e. either positive or negative class is prevalent)                
requires a distinct evaluation strategy. For example, ROC analysis at high specificity for the              
minority class; see Figure 2.  
● The procedure that was used to evaluate the performance of the trained model should also be                
discussed in detail as relevant also for other methods being compared. 
● When reporting final ML performance always report on unseen data (either validation set or test               
set). Training performance can be reported for self-consistency checks but not as a performance              
metric.  
● When performing method comparisons, these should be made against methods that are publicly             
available, baseline methods, or community-wide evaluation frameworks (e.g. CASP/CAFA) or          
combinations thereof.  
● When reporting the model performance, it is important to include confidence intervals using             
statistical mean and variance calculations to ensure stable results.  
● It is recommended that raw evaluation tables, equations, visualization, statistical tests and            
statistical testing code should be released to the community.  
 
Box 1: How to structure a Materials and Methods section 
 
Here we suggest a list of questions that must be asked about each section to ensure high quality of ML 
analysis. 
● Data ​: ​(this section is to be repeated separately for each dataset) 
○ Provenance​: What is the source of the data (database, publication, direct experiment)?            
How many data points are available in total for the positive (N​pos​) and negative (N ​neg​)               
cases? Has the dataset been previously used by other papers and/or is it recognized by the                
community? 
○ Data splits​: How many data points are in the training and test sets? Was a separate                
validation set used, and if yes, how large was it? Is the distribution of data types in the                  
training and test sets different? Is the distribution of data types in both training and test                
sets plotted?  
○ Redundancy between data splits​: How were the sets split? Are the training and test sets               
independent? How was this enforced (e.g. redundancy reduction to less than X% pairwise             
identity)? How does the distribution compare to previously published ML datasets?  
○ Availability of data​: Is the data, including the data splits used, released in a public forum?                
If yes, where (e.g. supporting material, URL)?  
 
● Optimization​: ​(this section is to be repeated separately for each trained model) 
○ Algorithm​: What is the ML algorithm class used? Is the ML algorithm new? If yes, why is                 
it not published in a ML journal, and why was it chosen over better known alternatives?  
○ Meta-predictions​: Does the model use data from other ML algorithms as input? If yes,              
which ones? Is it completely clear that training data of initial predictors and meta-predictor              
is independent of test data for the meta-predictor?  
○ Data encoding​: How was the data encoded and pre-processed for the ML algorithm? 
○ Parameters​: How many parameters (​p)​ are used in the model? How was ​p​ selected? 
○ Features​: How many features (​f) are used as input? Was feature selection performed? If              
yes, was it performed using the training set only?  
○ Fitting​: Is the number of parameters (​p) reasonable for the number of training points              
(N​pos​+N​neg​) and/or is the number of features (f) ​large (e.g. is p>>(N ​pos​+N​neg​) and/or f>100)?              
If yes, how was over-fitting ruled out? Conversely, if N​pos​+N ​neg ​seems very much larger              
than ​ p​ and/or ​f​ is small (e.g. N​pos​+N​neg​>>p and/or f<5) how was under-fitting ruled out?  
○ Availability of configuration​: Are the hyper-parameter configurations, model files and          
optimization parameters available? If yes, where (e.g. URL)?  
 
● Model​: ​(this section is to be repeated separately for each trained model) 
○ Interpretability​: Is the model blackbox, if so did you compare performance to transparent             
models? Is the model transparent, if so did you compare performance to blackbox models?              
Can you explain clearly why your model is transparent/interpretable?  
○ Execution time​: How much real-time does a single representative prediction require on a             
standard machine? (e.g. seconds on a desktop PC or high-performance computing cluster)  
○ Availability of software​: Is the source code released? Is a method to run the algorithm such                
as executable, web server, virtual machine or container instance released? If yes, where             
(e.g. URL)?  
 
● Evaluation​:  
○ Evaluation method​: How was the method evaluated? (E.g. cross-validation, independent          
dataset, novel experiments) 
○ Performance measures​: Which performance metrics are reported? Is this set          
representative?  
○ Comparison​: Was a comparison to publicly available methods performed on benchmark           
datasets? Was a comparison to simpler baselines performed?  
○ Confidence​: Do the performance metrics have confidence intervals? Are the results           
statistically significant to claim that the method is superior to others and baselines?  
○ Availability of evaluation ​: Are the raw evaluation files (e.g. assignments for comparison            
and baselines, statistical code, confusion matrices) available? If yes, where (e.g. URL)? 
 
The above description is shown in table format in the Supplementary Material.  
 
 
Conclusion  
The objective of our recommendations is to increase the transparency and reproducibility of ML methods               
for the reader, the reviewer, the experimentalist and the wider community. Although we refer to ML, our                 
recommendations should also be applied to any statistical and empirical methods. We recognize that              
these recommendations are not exhaustive and should be viewed as a consensus-based first iteration of a                
continuously evolving system of community self-review. One of the most pressing issues is to agree to a                 
standardized data structure to describe the most relevant features of the ML methods being presented. As                
a first step to address this issue, we recommend including a “ML summary table” as described here in                  
future ML studies. We recommend including the following sentence in the methods section of all papers:                
“To increase reproducibility of the machine learning method of this study, the machine learning summary               
table (Table X) is included in the supporting information as per consensus guidelines (with reference to                
this manuscript).” We also recommend that training and testing sets be made available for reanalysis to                
interested parties by including them as supporting information to the manuscript. 
The development of a standardized approach for reporting ML methods has major advantages in              
increasing the quality of publishing ML methods. First, the disparity in manuscripts of reporting key               
elements of the ML method can make reviewing and assessing the ML method challenging. Second,               
certain key statistics and metrics that may affect the validity of the publication’s conclusions are               
sometimes not mentioned at all. Third, there are unexplored opportunities associated with meta-analyses             
of ML datasets. Access to large sets of raw data can enhance both the comparison between methods and                  
facilitate the development of better performing methods, while reducing unnecessary repetition of data             
generation. We believe that our recommendations to include a “machine learning summary table” and the               
availability of raw data as described above will greatly benefit the ML community and improve its                
standing with the intended users of these methods. 
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Supplementary Material 
Supplementary Figure 1. The four major topics when developing machine learning: data, optimization, model              
and evaluation (DOME). These can be used for many specific applications, some of which are shown for cellular,                  
genomics, proteomics, post-translational modifications (PTMs) and metabolomic analysis. The impact of correct            
machine learning goes all the way to medical decisions and personalised medicine.  
 
 
  
Machine learning summary table: 
 
Data Provenance Source of data, data points (positive, N​pos​  / negative, N​neg ​). Used by 
previous papers and/or community. 
 Dataset splits Size of N​pos ​ and N​neg ​ of training set, validation set (if present), test set. 
Distribution of N​pos ​ and N​neg ​ across sets. 
(section to be 
repeated for 
each dataset) 
Redundancy 
between data 
splits 
Independence between sets. Strategy used to make examples 
representative (e.g. eliminating data points more similar than X%). 
Comparison relative to other datasets. 
 Availability of data Yes/no for datasets. If yes: Supporting information, website URL. 
Optimization Algorithm ML class (e.g. neural network, random forest, SVM). If novel approach, 
reason is it not previously published. 
(section to be 
repeated for 
each trained 
model) 
Meta-predictions Yes/No. If yes: how other methods are used and whether the datasets 
are clearly independent. 
 Data encoding How input data is transformed (e.g. global features, sliding window on 
sequence). 
 Parameters Number of ML model parameters (p), e.g. tunable weights in neural 
networks. Protocol used to select p. 
 Features Number of ML input features (f), i.e. encoding of data points. In case of 
feature selection: Protocol used, indicating whether it was performed 
on training data only. 
 Fitting Justification for excluding over- (if p >> N​pos, train​+N​neg, train​ or f > 100) and 
under-fitting (if p << N​pos, train​+N​neg, train​ or f < 5). 
 Availability of 
configuration 
Yes/no for hyper-parameter configuration and model files. If yes: 
Supporting information, website URL. 
Model Interpretability Black box/transparent and justification. Explanation whether the model 
was compared to the other class. 
(section to be 
repeated for 
each trained 
model) 
Execution time CPU time of single representative execution on standard hardware 
(e.g. seconds on desktop PC). 
 Availability of 
software 
Source code repository (e.g. GitHub), software container, website URL. 
Evaluation Evaluation method Cross-validation, independent dataset or novel experiments. 
 Performance 
measures 
Accuracy, sensitivity, specificity, etc. 
 Comparison Name of other methods and, if available, definition of baselines 
compared to. Justification of representativeness. 
 Confidence  Confidence intervals and statistical significance. Justification for 
claiming performance differences. 
 Availability of 
evaluation 
Yes/no for raw evaluation files (e.g. assignments for comparison and 
baselines, confusion matrices). If yes: Supporting information, website 
URL. 
 
 
 
Example tables for author reference: 
 
The following is an example for a primary ML summary table built from (Walsh et al., Bioinformatics 
2012). 
 
Data: ​X-ray 
disorder 
Provenance Protein Data Bank (PDB) X-ray structures until May 2008 (training) and 
from May 2008 until September 2010 (test). 3,813 proteins total. N​pos​  = 
44,433 residues. N​neg​ = 710,207 residues. Not previously used. 
 Dataset splits N​pos,train​  = 37,495. N​neg,train​ = 622,625. N​pos,test​  = 6,938. N​neg,test​ = 87,582 
residues. No separate validation set. 5.68% positives on training set. 
7.34% positives on test set. 
 Redundancy 
between data splits 
Maximum pairwise identity within and between training and test set is 
25% enforced with UniqueProt tool. 
 Availability of data Yes, URL: http://protein.bio.unipd.it/espritz/ 
Data: 
DisProt 
disorder 
Provenance DisProt version 3.7 (January 2008) for training set, DisProt version 5.7 
for test set. 536 proteins total. N​pos​  = 63,841 residues. N​neg ​ = 164,682 
residues. Not previously used. 
 Dataset splits N​pos,train​  = 56,414. N​neg,train​ = 163,010. N​pos,test​  = 7,427. N​neg,test​ = 1,672 
residues. No separate validation set. 25.71% positives on training set. 
41.04% positives on test set. 
 Redundancy 
between data splits 
Maximum pairwise identity within and between training and test set is 
40% enforced with UniqueProt tool. Less stringent threshold used to 
maintain adequate dataset size. 
 Availability of data Yes, URL: http://protein.bio.unipd.it/espritz/ 
Data: ​NMR 
disorder 
Provenance Protein Data Bank (PDB) NMR structures until May 2008 (training) and 
from May 2008 until September 2010 (test) analyzed using the Mobi 
software. 2,858 proteins total. N​pos​  = 40,368 residues. N​neg ​ = 192,170 
residues. Not previously used. 
 Dataset splits N​pos,train​  = 29,263. N​neg,train​ = 143,891. N​pos,test​  = 11,105. N​neg,test ​ = 48,279 
residues. No separate validation set. 16.9% positives on training set. 
18.7% positives on test set. 
 Redundancy 
between data splits 
Maximum pairwise identity within and between training and test set is 
25% enforced with UniqueProt tool. 
 Availability of data Yes, URL: http://protein.bio.unipd.it/espritz/ 
Optimization Algorithm BRNN (Bi-directional recurrent neural network) with ensemble 
averaging. 
 Meta-predictions No. 
 Data encoding Sliding window of length 23 residues on input sequence with “one hot” 
encoding (i.e. 20 inputs per residue). 
 Parameters ESpritz p = 4,647 to 5,886 depending on model used. No optimization. 
 Features ESpritz f = 460 for sliding window of 23 residues with 20 inputs per 
residue. No feature selection. 
 Fitting The number of training examples is between 30 and 100 times p, 
suggesting neither over- nor under-fitting. 
 Availability of 
configuration 
No. 
Model Interpretability Black box, as correlation between input and output is masked. No 
attempt was made to make the model transparent.  
 Execution time ESpritzS ca. 1 sec / protein, ESpritzP ca. 1,500 sec / protein on a 
single Intel Xeon core. 
 Availability of 
software 
Web server, URL: http://protein.bio.unipd.it/espritz/ 
Linux executable, URL: http://protein.bio.unipd.it/download/ 
Evaluation Evaluation method Independent datasets. 
 Performance 
measures 
Accuracy, sensitivity, specificity, selectivity, F-measure, MCC, AUC are 
standard. S​w ​ = Sens + Spec -1. 
 Comparison Disopred, MULTICOM, DisEMBL, IUpred, PONDR-FIT, Spritz, CSpritz. 
Wide range of popular predictors used for comparison. 
 Confidence  Bootstrapping was used to estimate statistical significance as in 
CASP-8 (Noivirt-Brik et al, Proteins 2009). 80% of target proteins were 
randomly selected 1000 times, and the standard error of the scores 
was 
calculated (i.e. 1.96 × standard_error gives 95% confidence around 
mean for normal distributions). 
 Availability of 
evaluation 
No. 
 
 
 
The following is an example for meta-predictor ML summary built from (Necci et al., Bioinformatics 
2017). 
 
Data Provenance Protein Data Bank (PDB). X-ray structures missing residues. N​pos​ = 
339,603 residues. N​neg ​ = 6,168,717 residues. Previously used in 
(Walsh et al., Bioinformatics 2015) as an independent benchmark set. 
 Dataset splits training set: N/A 
N​pos,test​ = 339,603 residues. N​neg,test​ = 6,168,717 residues. No validation 
set. 5.22% positives on test set. 
 Redundancy 
between data splits 
Not applicable. 
 Availability of data Yes, URL: http://protein.bio.unipd.it/mobidblite/ 
Optimization Algorithm Majority-based consensus classification based on 8 primary ML 
methods and post-processing. 
 Meta-predictions Yes, predictor output is a binary prediction computed from the 
consensus of other methods; Independence of training sets of other 
methods with test set of meta-predictor was not tested since datasets 
from other methods were not available. 
 Data encoding Label-wise average of 8 binary predictions. 
 Parameters p = 3 (Consensus score threshold, expansion-erosion window, length 
threshold). No optimization. 
 Features Not applicable. 
 Fitting Single input ML methods are used with default parameters. 
Optimization is a simple majority. 
 Availability of 
configuration 
Not applicable. 
Model Interpretability Transparent, in so far as meta-prediction is concerned. Consensus and 
post processing over other methods predictions (which are mostly 
balck boxes).​ ​No attempt was made to make the meta-prediction a 
black box.  
 Execution time ca. 1 second per representative on a desktop PC. 
 Availability of 
software 
Yes, URL: http://protein.bio.unipd.it/mobidblite/ 
Evaluation Evaluation method Independent dataset 
 Performance 
measures 
Balanced Accuracy, Precision, Sensitivity, Specificity, F1, MCC. 
 Comparison DisEmbl-465, DisEmbl-HL, ESpritz Disprot, ESpritz NMR, ESpritz 
Xray, Globplot, IUPred long, IUPred short, VSL2b. Chosen methods 
are the methods from which the meta prediction is obtained. 
 Confidence  Not calculated. 
 Availability of 
evaluation 
No. 
 
 
